

Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

## Press Release



ASKA Pharmaceutical Holdings Co., Ltd.

### **ASKA Files Application with Japanese Authorities for Manufacturing and Marketing Approval of Emergency Contraceptive Pill “NORLEVO” as Switch OTC Drug**

---

**TOKYO, May 15, 2025** – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter “ASKA”), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (TSE: 4886), announced that ASKA filed an application with Japanese authorities for manufacturing and marketing approval of the emergency contraceptive pill “NORLEVO” as a switch OTC drug.

Regarding the switch to OTC use of emergency contraceptive pills, the Evaluation and Review Committee began examining the switch to OTC use of emergency-contraceptive pills in 2021. A survey project to prepare an environment for the proper sale of emergency contraceptive pills (test sales of emergency contraceptive pills) is currently being implemented.

Under these circumstances, in order to build a system that can respond to various requests, ASKA filed an application for manufacturing and marketing approval in June 2024. Although the specific timing of approval has not yet been decided, ASKA will keep a close eye on the situation and disclose any information that needs to be announced in a timely and appropriate manner.

---

#### **Media Contacts**

ASKA Pharmaceutical Holdings Co., Ltd.  
Corporate Planning Department  
Tel: +81-3-5484-8366  
Email: [kouhou@aska-pharma.co.jp](mailto:kouhou@aska-pharma.co.jp)